C. Fugazza

Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial

M. Reni, A. Rognone, E. Villa, 2011, Chemotherapy.

XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.

M. Reni, P. Passoni, A. Rognone, 2010, Anticancer research.

Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancers

M. Reni, A. Rognone, E. Villa, 2009, Journal of chemotherapy.

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma

M. Reni, M. Falconi, P. Passoni, 2016, British Journal of Cancer.

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

M. Reni, M. Falconi, S. Partelli, 2018, European journal of cancer.

Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.

M. Reni, L. Gianni, E. Mazza, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.

M. Reni, M. Milella, A. Novarino, 2013, European journal of cancer.

Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial

M. Reni, P. Passoni, M. Tronconi, 2012, Annals of Surgical Oncology.

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

M. Reni, P. Passoni, C. Doglioni, 2011, Cancer Chemotherapy and Pharmacology.

Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma

M. Reni, P. Passoni, A. Rognone, 2009, Cancer.

Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma

M. Reni, M. Falconi, P. Passoni, 2016 .

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer

A. Brandes, M. Reni, P. Passoni, 2006, British Journal of Cancer.

B01*A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back

M. Reni, M. Falconi, P. Passoni, 2016 .